News and Trends 1 Jul 2020
Swiss Regenerative Medicine Biotech Closes €19M Series B
The regenerative medicine startup Cutiss has raised €18.8M (CHF 20M) to commercialize its personalized skin graft treatment for burn patients in Switzerland and the European Union around 2022. This is the final closing of a Series B round announced earlier this month. The lead investor in the oversubscribed round was the Swiss firm Gisev Family […]